← Back to guidelines
Hematology1 paper

Acquired thrombotic thrombocytopenic purpura

Last edited: 4/10/2026

Overview

Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy (TMA) characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and microvascular thrombosis 1. It is defined by these three core features 1.

Diagnosis

  • Diagnosis is based on thrombocytopenia, MAHA, and microvascular thrombosis 1.
  • All TTP cases in England should be managed within designated regional centers 1.
  • Management

  • Management of TTP and related TMAs, including complement-mediated hemolytic uremic syndrome (CMHUS), is provided 1.
  • Key Recommendations

  • All TTP cases should be managed within designated regional centers as per NHSE commissioning for highly specialized services 1. (Evidence: Expert opinion)
  • Healthcare professionals should be provided with clear, up-to-date, and practical guidance on the management of TTP and related TMAs 1. (Evidence: Expert opinion)
  • References

    1 Scully M, Rayment R, Clark A, Westwood JP, Cranfield T, Gooding R et al.. A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. British journal of haematology 2023. link

    Original source

    1. [1]
      A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.Scully M, Rayment R, Clark A, Westwood JP, Cranfield T, Gooding R et al. British journal of haematology (2023)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG